Skip to main content

Advertisement

Advertisement

World

Pfizer to ship 13 million COVID-19 vaccine doses per week to US by mid-March: Executive

Pfizer to ship 13 million COVID-19 vaccine doses per week to US by mid-March: Executive

FILE PHOTO: A photo illustration showing a small bottle labeled "Coronavirus COVID-19 Vaccine" and a medical syringe in front of displayed Pfizer logo. (Photo: REUTERS/Dado Ruvic)

Pfizer expects to deliver more than 13 million doses of its COVID-19 vaccine per week to the United States by the middle of March, more than doubling its shipments from early February, a top Pfizer executive said in prepared testimony ahead of a Tuesday (Feb 23) congressional hearing.

Pfizer is on track to deliver 120 million doses of its two-dose regimen by the end of March, said John Young, Pfizer's chief business officer.

Pfizer is also prepared to provide a total of 300 million shots to the United States by the end of July and has raised global production expectations for 2021 to at least 2 billion doses, he said.

READ: Pfizer to double weekly US output of vaccine in next few weeks, says CEO

In his own prepared remarks, Moderna President Stephen Hoge said the drugmaker plans to deliver 100 million doses of its two-dose shot by the end of March, and 300 million by the end of July.

Johnson & Johnson believes it will be able to ship at least 20 million doses of its single-dose shot to the United States by the end of March after receiving US regulatory authorisation and 100 million doses by mid-year 2021, said Vice President of Medical Affairs Richard Nettles.

READ: US mourns 500,000 lives lost to COVID-19

The comments were prepared ahead of a US congressional hearing on vaccine availability to be held by the House Committee on Energy and Commerce on Tuesday as the United States crossed the staggering milestone of 500,000 COVID-19 deaths.

The remarks put the United States on track to receive 240 million doses by the end of March, enough to inoculate 130 million Americans, and 700 million doses by mid-year.

READ: US storms delay COVID-19 vaccines in all 50 states, says White House

AstraZeneca, which is running a US trial for its coronavirus vaccine, believes it can quickly adapt its shot to new variants of the virus in its laboratory, said Ruud Dobber, company president, North America.

A highly contagious COVID-19 variant has become prevalent in South Africa and has turned up in several US states.

BOOKMARK THIS: Our comprehensive coverage of the coronavirus outbreak and its developments

Download our app or subscribe to our Telegram channel for the latest updates on the coronavirus outbreak: https://cna.asia/telegram

Source: Reuters/ga

Advertisement

Also worth reading

Advertisement